Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Cancer Research Communications
|
June 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Eric D Eisenmann, Ronan Swords, Ying Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2019
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Naseema Gangat, Christian Marinaccio, Ronan Swords, et al.
Blood Cancer Discovery
|
May 21, 2025
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study
Curtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML
Joshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Haematologica
|
April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Michael J Hochman, Amy S Ruppert, Ying Huang, et al.
Blood Neoplasia
|
April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia
Uma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Leukemia
|
July 22, 2018
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Robert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
The New England Journal of Medicine
|
June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Curtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Cancer Research Communications
|
June 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Eric D Eisenmann, Ronan Swords, Ying Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2019
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Naseema Gangat, Christian Marinaccio, Ronan Swords, et al.
Blood Cancer Discovery
|
May 21, 2025
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study
Curtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML
Joshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Haematologica
|
April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Michael J Hochman, Amy S Ruppert, Ying Huang, et al.
Blood Neoplasia
|
April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia
Uma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Leukemia
|
July 22, 2018
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Robert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
The New England Journal of Medicine
|
June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Curtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.
Page
of 6